Clinical Trial Update: Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing subcutaneous EPO HEXAL to ERYPO in predialysis chronic renal insufficiency patients; study terminated with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia in Chronic Kidney Disease
• Renal Insufficiency

Drugs mentioned

• EPO HEXAL (epoetin alfa? (subcutaneous formulation))
• ERYPO

Snippet

Sponsor: Sandoz | Conditions: Anemia, Chronic Renal Insufficiency | Phase 3 | Status: TERMINATED | Results posted: 2018-02-05